Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allovir Inc
(NQ:
ALVR
)
0.7745
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allovir Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Root Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
June 22, 2023
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 100.8% to $2.65 in pre-market trading after dropping 43% on Wednesday.
Via
Benzinga
AlloVir, DigitalOcean And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 22, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. AlloVir, Inc. (NASDAQ: ALVR) shares dipped 24.1% to $3.74 in pre-market...
Via
Benzinga
AlloVir Announces Pricing of Public Offering of Common Stock
June 21, 2023
From
AlloVir, Inc.
Via
Business Wire
Why AlloVir Stock Is Tumbling After Hours
June 21, 2023
AlloVir Inc (NASDAQ: ALVR) shares are trading lower in Wednesday's after-hours session after the company proposed a public offering.
Via
Benzinga
AlloVir: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
AlloVir Announces Proposed Public Offering of Common Stock
June 21, 2023
From
AlloVir, Inc.
Via
Business Wire
Why Shares of AlloVir Jumped This Week
June 09, 2023
The company's lead therapy fared well in preventing infections for kidney transplant patients.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 06, 2023
Via
Benzinga
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
June 05, 2023
From
AlloVir, Inc.
Via
Business Wire
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 06, 2023
Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq.
Via
Benzinga
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 16, 2023
From
AlloVir
Via
Business Wire
AlloVir Reports First Quarter 2023 Financial Results
May 04, 2023
From
AlloVir
Via
Business Wire
AlloVir to Present at the BofA Securities 2023 Health Care Conference
May 01, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections
April 26, 2023
AlloVir Inc (NASDAQ: ALVR) announced the presentation of long-term, follow-up data from the Phase 2 study of posoleucel to prevent infections from six viruses in allogeneic hematopoietic cell...
Via
Benzinga
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
April 26, 2023
From
AlloVir, Inc.
Via
Business Wire
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
April 13, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 09, 2023
Via
Benzinga
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
February 23, 2023
From
AlloVir
Via
Business Wire
AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall
February 15, 2023
Via
Benzinga
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
February 15, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
February 15, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir to Participate in the SVB Securities Global Biopharma Conference
February 01, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
January 09, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
AlloVir, Inc.
Via
Business Wire
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
December 10, 2022
From
AlloVir
Via
Business Wire
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 15, 2022
From
AlloVir
Via
Business Wire
AlloVir: Q3 Earnings Insights
November 03, 2022
AlloVir (NASDAQ:ALVR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings AlloVir beat estimated earnings by...
Via
Benzinga
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
November 03, 2022
From
AlloVir, Inc.
Via
Business Wire
AlloVir Reports Third Quarter 2022 Financial Results
November 03, 2022
From
AlloVir, Inc.
Via
Business Wire
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
October 21, 2022
Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.